In short
This article discusses ongoing clinical trials investigating the use of a Humanised IgG2 Monoclonal Antibody Against Interleukin-6 (RO7200220) for the treatment of uveitic macular edema. These Phase III studies aim to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of this novel drug when administered intravitreally in patients with this eye condition. The trials are designed to compare the effects of RO7200220 with a sham treatment in improving visual function and reducing macular edema.
At a glance
- Drug Name
- RO7200220 (Humanised IgG2 Monoclonal Antibody Against Interleukin-6)
- Condition Studied
- Uveitic Macular Edema (UME)
- Study Phase
- Phase III
- Study Design
- Multicenter, randomized, double-masked, sham-controlled
- Primary Objective
- Evaluate efficacy on functional outcomes compared to sham treatment
- Key Inclusion Criteria
- Diagnosis of UME, specific BCVA range, non-infectious uveitis
- Key Exclusion Criteria
- Active infections, major ocular conditions, recent eye surgeries or treatments
- Primary Endpoint
- Proportion of participants with ≥15 letter improvement in BCVA at Week 16
- Key Secondary Endpoints
- Changes in BCVA and CST, UME resolution, safety assessments
- Administration Route
- Intravitreal injection
What is RO7200220?
RO7200220 is a new medication being studied for the treatment of uveitic macular edema. It is also known as IL6-Mab, which stands for Interleukin-6 Monoclonal Antibody. More specifically, it is a humanized IgG2 monoclonal antibody that targets interleukin-6, an important protein involved in inflammation.
What is Uveitic Macular Edema?
Uveitic macular edema (UME) is a condition where fluid builds up in the macula, the central part of the retina responsible for sharp, detailed vision. This swelling is caused by inflammation in the eye due to uveitis, which is an inflammatory disease affecting the middle layer of the eye. UME can lead to vision problems and, if left untreated, may cause permanent vision loss.
How does RO7200220 work?
RO7200220 works by targeting and blocking interleukin-6 (IL-6), a protein that plays a key role in inflammation. By reducing the activity of IL-6, RO7200220 aims to decrease inflammation in the eye and reduce the swelling in the macula. This could potentially improve vision and prevent further damage to the eye.
Clinical Trials
RO7200220 is currently being studied in Phase III clinical trials. These trials are designed to evaluate how well the medication works and how safe it is for patients with uveitic macular edema. The studies are: Multicenter: Conducted at multiple hospitals or clinics Randomized: Patients are randomly assigned to receive either RO7200220 or a sham (placebo) treatment Double-masked: Neither the patients nor the doctors know who is receiving the actual medication Sham-controlled: Some patients receive a sham treatment to compare the effects with those receiving RO7200220 The trials aim to assess the medication's efficacy, safety, how it moves through the body (pharmacokinetics), and how it affects the body (pharmacodynamics).
Potential Benefits
The main goal of the RO7200220 treatment is to improve vision in patients with uveitic macular edema. Specifically, the trials are looking at: Improvement in visual acuity (ability to see clearly) Reduction in macular thickness (less swelling in the macula) Resolution of macular edema Improved quality of life related to vision These potential benefits are being measured at various time points throughout the study, including 16 weeks, 20 weeks, and 52 weeks after starting treatment.
Administration and Dosage
RO7200220 is administered as an intravitreal injection. This means the medication is injected directly into the vitreous, the gel-like substance in the back of the eye. The maximum daily dose being studied is 1 mg, with a total maximum dose of 52 mg over the course of 52 weeks. This suggests that patients may receive multiple injections over the course of the treatment period.
Safety and Side Effects
As with any medical treatment, safety is a crucial aspect of the RO7200220 clinical trials. The researchers are carefully monitoring for any side effects or adverse events. They are particularly interested in: Ocular (eye-related) side effects Non-ocular side effects Changes in eye pressure Effects on the corneal endothelial cells (cells lining the inner surface of the cornea) The trials also include long-term follow-up to assess the safety of RO7200220 over an extended period.
Who Can Participate in the Clinical Trials?
The clinical trials have specific criteria for who can participate. Generally, eligible participants include: Patients diagnosed with macular edema associated with non-infectious uveitis Individuals with a certain level of visual acuity (between 20/40 and 20/400) Patients with active or inactive, acute, or chronic non-infectious uveitis of any type However, there are also conditions that may exclude someone from participating, such as: Certain infections (like tuberculosis, syphilis, or HIV) Major eye conditions that might interfere with the study results Recent eye surgeries or treatments Uncontrolled eye pressure or glaucoma It's important to note that only a healthcare professional can determine if someone is eligible to participate in these clinical trials.